US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Parabilis Medicines / Equity Capital Markets

<ul>
<li>IPO priced above range with ~10x oversubscription; opened +66.8%, reflecting exceptional institutional demand and tight float dynamics.</li>
<li>Strong momentum driven by strategic backing and collaboration with Regeneron Pharmaceuticals supporting deal credibility and investor conviction.</li>
<li>Near-Term trading likely driven by volatility and profit-taking, but strong demand backdrop supports potential follow-through.</li>
</ul>


IPO priced above range with ~10x oversubscription; opened +66.8%, reflecting exceptional institutional demand and tight float dynamics.
Strong momentum driven by strategic backing and collaboration with Regeneron Pharmaceuticals supporting deal credibility and investor conviction.
Near-Term trading likely driven by volatility and profit-taking, but strong demand backdrop supports potential follow-through.


Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul>
<li>Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering , marketing 33.33 million shares at a price range of $17.00 to $19.00 per share .</li>
<li>At the midpoint of the proposed range, the Cambridge, Massachusetts-based biotechnology company would command an estimated market capitalization of approximately $2.14 billion .</li>
<li>The offering is being led by Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital .</li>
</ul>


Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering , marketing 33.33 million shares at a price range of $17.00 to $19.00 per share .
At the midpoint of the proposed range, the Cambridge, Massachusetts-based biotechnology company would command an estimated market capitalization of approximately $2.14 billion .
The offering is being led by Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital .


Parabilis Medicines Eyes $600 Million IPO as Lead Cancer Program Approaches Registrational Development

<ul>
<li>Regeneron invested $75 million alongside the IPO and committed $50 million upfront, providing major third-party validation of the Helicon platform.</li>
<li>Lead candidate zolucatetide has shown encouraging early efficacy, including a 74% objective response rate in desmoid tumor patients.</li>
<li>Backed by premier healthcare investors including FMR, RA Capital, ARCH, venBio, GV, and Cormorant, supporting institutional credibility.</li>
</ul>


Regeneron invested $75 million alongside the IPO and committed $50 million upfront, providing major third-party validation of the Helicon platform.
Lead candidate zolucatetide has shown encouraging early efficacy, including a 74% objective response rate in desmoid tumor patients.
Backed by premier healthcare investors including FMR, RA Capital, ARCH, venBio, GV, and Cormorant, supporting institutional credibility.


Parabilis Medicines, Inc. (PBLS): Regeneron Validation Powers Parabilis Toward Public Markets

<ul>
<li>Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.</li>
<li>Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.</li>
<li>Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.</li>
</ul>


Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.
Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.
Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.


Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

<ul><li>✅ IPO PROPHET RATING: 8.34/10 🏦 Deal Quality &amp; Underwriters: 9/10 Parabilis Medicines is coming to market on Nasdaq under the ticker PBLS, offering 25 million shares at $17 to $19 and targeting approximately $450 million in proceeds.</li><li>The company is developing a novel class of engineered peptide therapeutics designed to address historically difficult-to-target disease pathways, with an initial focus on oncology indications and other high-value therapeutic opportunities.</li><li>The company's proprietary Helicon platform represents a differentiated approach within precision medicine and targeted drug development.</li></ul>

✅ IPO PROPHET RATING: 8.34/10 🏦 Deal Quality &amp; Underwriters: 9/10 Parabilis Medicines is coming to market on Nasdaq under the ticker PBLS, offering 25 million shares at $17 to $19 and targeting approximately $450 million in proceeds.The company is developing a novel class of engineered peptide therapeutics designed to address historically difficult-to-target disease pathways, with an initial focus on oncology indications and other high-value therapeutic opportunities.The company's proprietary Helicon platform represents a differentiated approach within precision medicine and targeted drug development.

United States

Parabilis Medicines, Inc. is a biopharmaceutical company. The Company develops medicines for the treatment cancer. Parabilis Medicines operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Parabilis Medicines (PBLS US)

Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop

IPO priced above range with strong institutional demand and collaboration with Regeneron driving exceptional opening performance and potential...

IPO Boutique

Parabilis Medicines Eyes $600 Million IPO as Lead Cancer Program Approaches Registrational Development

Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering , marketing 33.33 million shares at a price range...

IPO Prophet

Parabilis Medicines, Inc. (PBLS): Regeneron Validation Powers Parabilis Toward Public Markets

Regeneron's $75 million investment in Helicon's IPO validates the platform, with promising results for lead candidate zolucatetide in desmoid...

IPO Boutique

Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.

IPO Boutique

IPO Rating: Parabilis Medicines, Inc.

✅ IPO PROPHET RATING: 8.34/10 🏦 Deal Quality & Underwriters: 9/10 Parabilis Medicines is coming to market on Nasdaq under the ticker PBLS,...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop

​IPO priced above range with strong institutional demand and collaboration with Regeneron driving exceptional opening performance and potential...

IPO Boutique

Parabilis Medicines Eyes $600 Million IPO as Lead Cancer Program Approaches Registrational Development

Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering , marketing 33.33 million shares at a price range...

IPO Prophet

Parabilis Medicines, Inc. (PBLS): Regeneron Validation Powers Parabilis Toward Public Markets

​Regeneron's $75 million investment in Helicon's IPO validates the platform, with promising results for lead candidate zolucatetide in desmoid...

IPO Boutique

Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

​Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.

IPO Boutique

IPO Rating: Parabilis Medicines, Inc.

✅ IPO PROPHET RATING: 8.34/10 🏦 Deal Quality & Underwriters: 9/10 Parabilis Medicines is coming to market on Nasdaq under the ticker PBLS,...

IPO Prophet

IPO priced above range with strong institutional demand and collaboration with Regeneron driving exceptional opening performance and potential...

Regeneron's $75 million investment in Helicon's IPO validates the platform, with promising results for lead candidate zolucatetide in desmoid...

Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.